news-WFH-Congress-banner-May04-EN

LAST CHANCE TO REGISTER VIRTUALLY FOR THE WFH 2022 WORLD CONGRESS!

There is still time to register virtually for the WFH 2022 World Congress and enjoy select sessions and content from the comfort of your home or office.

Also available in: Français Español

To all of the Dentists, Nurses, Laboratory Scientists, Orthopedic surgeons, and Physiotherapists attending congress – with the purchase of the Pro+ add-on, you will gain access to exclusive online only sessions within each of your fields—both live and on-demand.

Visit the Congress website to further explore your options, review which sessions are included in both the virtual registration and the Pro+ add-on, and find out more about the other perks you will be able to enjoy:

WFH 2022 World Congress Virtual Attendees

Virtual attendees will be able to access live and on demand content—and enjoy many networking opportunities—through our Virtual Platform. To learn more about the features and functionalities of our platform, watch the following short video:

WFH 2022 World Congress App now available!

Make sure to download the Congress mobile application, by Event App, to have quick access to the program, speaker information, floorplan and more. Scan the QR code below with your smartphone to download the app.

Use event app code: wfh22

Apple app store
Google Play store

Alternatively, you can click below links to download the app:

WFH 2022 Medical Program Committee announces a third late-breaking session to its scientific lineup at the World Congress!

The WFH 2022 World Congress will feature three late-breaking science sessions over the three days. The late breakers include new data in clinical trial research:

Late-breaking Clinical Research 1: Monday, May 9 – 13:30 to 14:30

Topics:

  • A Phase 1 Sequential Pharmacokinetic (PK) Evaluation of Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Severe Hemophilia A
  • Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for Valactogene Roxaparvovec vector in altering cell growth
  • Immune suppression following Gene Therapy in Hemophilia Late-Breaking Science 2: Hypertension: Local, Global and Pandemic Impacts

Late-Breaking Clinical Research 2: Tuesday, May 10 – 13:30 to 14:30

Topics:

  • Health-related quality of life over two years following valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from GENEr8-1
  • Rondoraptivon pegol (BT200) for the treatment of type 2B von Willebrand disease
  • Gene Editing for Rare Diseases: Transthyretin-Amyloidosis and Hemophilia B

Late-Breaking Clinical Research 3: Wednesday, May 11 – 13:30 to 14:30

Topics:

  • Pain adversely impacts quality of life in people with hemophilia: The Perceptions of Pain in Hemophilia study
  • Use of magnetic resonance imaging (MRI) and Hemophilia Joint Health Score (HJHS) to assess joint status after two years of a personalized rehabilitation program in patients with severe hemophilia with inhibitor (PWHI) on long-term prophylaxis with activated prothrombin complex concentrate (aPCC)
  • Human Liver Biopsy Analysis showed interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

Joining in person?

On-site registrations will be accepted at the Palais des congrès as of 7:30 a.m. on Sunday, May 8 at the registration desk located in the exhibition hall (room 220BCD).

WFH 2022 World Congress

May 8 to 11, 2022

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.